167 related articles for article (PubMed ID: 32487509)
1. Quality of Life and Climacteric Symptoms in Postmenopausal Women Receiving Hormone Therapy for Breast Cancer.
Macruz CF; Lima SMRR; Postigo S; Martins MM; Lucarelli AP; de Oliveira VM
J Obstet Gynaecol Can; 2020 Oct; 42(10):1243-1247. PubMed ID: 32487509
[TBL] [Abstract][Full Text] [Related]
2. Effects of
Furtado Macruz C; Lima SMRR
J Obstet Gynaecol; 2022 Oct; 42(7):3236-3240. PubMed ID: 35993523
[TBL] [Abstract][Full Text] [Related]
3. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.
Sismondi P; Kimmig R; Kubista E; Biglia N; Egberts J; Mulder R; Planellas J; Moggio G; Mol-Arts M; Kenemans P
Maturitas; 2011 Dec; 70(4):365-72. PubMed ID: 22030384
[TBL] [Abstract][Full Text] [Related]
4. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
5. Validation of the traditional Chinese version of the Menopausal Rating Scale with WHOQOL-BREF.
Wu HC; Wen SH; Hwang JS; Huang SC
Climacteric; 2015 Oct; 18(5):750-6. PubMed ID: 26029986
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
[TBL] [Abstract][Full Text] [Related]
7. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
8. Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors.
Yeo W; Pang E; Liem GS; Suen JJS; Ng RYW; Yip CCH; Li L; Yip CHW; Mo FKF
Health Qual Life Outcomes; 2020 Feb; 18(1):24. PubMed ID: 32041627
[TBL] [Abstract][Full Text] [Related]
9. Quality of life and menopausal symptoms in women with liver transplants.
Baccaro LF; Boin Ide F; Costa-Paiva L; Pinto-Neto AM
Rev Bras Ginecol Obstet; 2013 Mar; 35(3):103-10. PubMed ID: 23538468
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
11. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
13. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
14. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
[TBL] [Abstract][Full Text] [Related]
15. Combined exercise training reduces climacteric symptoms without the additive effects of isoflavone supplementation: A clinical, controlled, randomised, double-blind study.
Costa JG; Giolo JS; Mariano IM; Batista JP; Ribeiro ALA; Souza TCF; de Oliveira EP; Resende APM; Puga GM
Nutr Health; 2017 Dec; 23(4):271-279. PubMed ID: 29214925
[TBL] [Abstract][Full Text] [Related]
16. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
17. The 5HTT and MAO-A polymorphisms associate with depressive mood and climacteric symptoms in postmenopausal women.
Grochans E; Grzywacz A; Jurczak A; Samochowiec A; Karakiewicz B; Brodowska A; Starczewski A; Samochowiec J
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():125-30. PubMed ID: 23707423
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in Brazilian breast cancer survivors age 45-65 years: associated factors.
Conde DM; Pinto-Neto AM; Cabello C; Santos-Sá D; Costa-Paiva L; Martinez EZ
Breast J; 2005; 11(6):425-32. PubMed ID: 16297087
[TBL] [Abstract][Full Text] [Related]
19. Finished herbal product as an alternative treatment for menopausal symptoms in climacteric women.
Lai JN; Hwang JS; Chen HJ; Wang JD
J Altern Complement Med; 2005 Dec; 11(6):1075-84. PubMed ID: 16398600
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Sheng JY; Blackford AL; Bardia A; Venkat R; Rosson G; Giles J; Hayes DF; Jeter SC; Zhang Z; Hayden J; Nguyen A; Storniolo AM; Tarpinian K; Henry NL; Stearns V
Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
